Drugs / Trizivir
last change Nov 2014 re-read 2 minutes ago

Trizivir

Developed for
HIV infectious disease
Investigated by
GlaxoSmithKline · Boehringer Ingelheim · International Antiviral Therapy Evaluation Center · Rijnstate Hospital

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Trizivir 2000-12-27 europa.eu
Approved US (FDA) TRIZIVIR 2000-11-14 fda.gov

Trials 4 · a red edge is where a trial was stopped

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 32 trials
Phase 3 NCT00405925 Mar 2003 → Aug 2009 HIV infectious disease Rijnstate Hospital Completed No outcome recorded
Phase 3 NCT00043888 Jan 2002 → May 2003 HIV infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 42 trials
Phase 4 NCT00449436 Jan 2005 → Dec 2007 HIV infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 4 NCT00127972 Feb 2004 → Apr 2007 HIV infectious disease International Antiviral Therapy Evaluation Center Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT00960622 Comparator Aug 2006 → Jul 2009 HIV infectious disease St. Luke's-Roosevelt Hospital Center Completed No outcome recorded
Phase 4 NCT00979706 Comparator Mar 2005 → Nov 2014 HIV infectious disease Juan A. Arnaiz Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as TRIZIVIR “Patients assigned to this arm will receive Trizivir and kaletra.” NCT00979706
5

NCT00043888

NCT00405925

NCT00960622

NCT00449436

NCT00127972